Physician profile
Aaron Dahl
NPI 1891172813
$11,598.49
in general payments reported to CMS, 2019-2025
33 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $425 · 2021: $1,820 · 2022: $1,987 · 2023: $2,204 · 2024: $2,511 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,366.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,490.68 | 2021-2025 | Vraylar |
| Corium, LLC | $1,347.38 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $1,114.00 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,035.97 | 2020-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $747.30 | 2020-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $590.36 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $528.24 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $494.37 | 2020-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $481.72 | 2021-2025 | Qelbree |
| Lundbeck LLC | $464.91 | 2020-2025 | Rexulti |
| Almatica Pharma LLC | $415.98 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $355.41 | 2020-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $335.94 | 2021-2023 | Spravato |
| Neurocrine Biosciences, INC. | $331.76 | 2020-2025 | Ingrezza |
| Alkermes, INC. | $322.81 | 2021-2025 | Lybalvi, Aristada |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $310.00 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Allergan, INC. | $177.34 | 2020 | |
| Bausch Health US, LLC | $176.32 | 2021-2025 | Aplenzin |
| Vanda Pharmaceuticals INC. | $119.67 | 2022-2025 | Fanapt, Hetlioz |
| Harmony Biosciences LLC | $111.83 | 2022-2025 | Wakix |
| Biogen, INC. | $107.04 | 2024-2025 | Zurzuvae |
| Eisai INC. | $101.81 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $100.14 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $65.42 | 2024-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $62.48 | 2022-2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $44.79 | 2024-2025 | Relexxii |
| Medtronic, INC. | $36.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.42 | 2025 | Cobenfy |
| Actelion Pharmaceuticals US, INC. | $27.92 | 2021 | |
| Boston Scientific Corporation | $23.73 | 2021 | |
| Tempus Ai, INC | $16.63 | 2024 | Tempus Pixel |
| Neos Therapeutics, LP | $15.36 | 2023 | Adzenys Xr-Odt |
| Alfasigma USA, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Dahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.